PT  - JOURNAL ARTICLE
AU  - Teherán, Aníbal A.
AU  - Camero, Gabriel
AU  - de la Guardia, Ronald Prado
AU  - Hernández, Carolina
AU  - Herrera, Giovanny
AU  - Pombo, Luis M.
AU  - Ávila, Albert A.
AU  - Flórez, Carolina
AU  - Barros, Esther C.
AU  - Perez-Garcia, Luis A.
AU  - Paniz-Mondolfi, Alberto
AU  - Ramírez, Juan David
TI  - Epidemiological characterization of asymptomatic carriers of COVID-19 in Colombia
AID  - 10.1101/2020.06.18.20134734
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.18.20134734
4099  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134734.short
4100  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134734.full
AB  - Objective Asymptomatic carriers (AC) of the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) represent an important source of spread for Coronavirus Disease 2019 (COVID-19). Early diagnosis of these cases is a powerful tool to control the pandemic. Our objective was to characterize patients with AC status and identify associated sociodemographic factors.Methods Using a cross-sectional design and the national database of daily occurrence of COVID-19, we characterized both socially and demographically all ACs. Additional Correspondence Analysis and Logistic Regression Model were performed to identify characteristics associated with AC state (OR, 95% CI).Results 2338 ACs (11.8%; 95% CI, 11.3-12.2%) were identified, mainly in epidemiological week 18 [EW] (3.98; 3.24-4.90). Age ≤ 39 years (1.56; 1.42-1.72). Male sex (1.39; 1.26-1.53), cases imported from Argentina, Spain, Peru, Brazil, Costa Rica or Mexico (3.37; 1.47-7.71) and autochthonous cases (4.35; 2.12-8.93) increased the risk of identifying AC. We also identified groups of departments with moderate (3.68; 3.13-4.33) and strong (8.31; 6.10-7.46) association with AC.Discussion Sociodemographic characteristics strongly associated with AC were identified, which may explain its epidemiological relevance and usefulness to optimize mass screening strategies and prevent person-to-person transmission.Competing Interest StatementThe authors have declared no competing interest.Funding Statementnot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As this manuscript used public data, not IRB was needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are in their relevant supporting information